ENGOT-EN5/GOG-3055/SIENDO: Selinexor in Endometrial Cancer (Phase II)
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced
Study Summaries
GOG 3007: Megace Tamoxifen vs Letrozole Everolimus
Both treatment arms demonstrated clinically meaningful efficacy in patients with recurrent endometrial carcinoma. The combination of everolimus and letrozole showed a non-significant trend toward improved survival outcomes compared to standard hormonal therapy.
TOTEM Trial: Intensive vs. Minimalist Follow-up in Endometrial Cancer
An intensive follow-up in patients treated for endometrial cancer does not improve overall survival or relapse detection significantly compared to a minimalist approach.
GOG 122: Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma
AP chemotherapy significantly improved both progression-free and overall survival compared to WAI in patients with advanced endometrial carcinoma, although it was associated with greater acute toxicity.
PORTEC 1: EBRT vs. Observation in Endometrial Cancer
While postoperative radiotherapy reduces locoregional recurrence, it does not impact overall survival and increases treatment-related morbidity.
GOG 99: Surgery With or Without EBRT in Intermediate Risk Endometrial Adenocarcinoma
MITO 23
Trabectedin did not improve median OS and demonstrated a worse safety profile compared to physician’s choice chemotherapy.
FIRES Trial: Sentinel LND in Endometrial Cancer
SENTOR Trial: Sentinel LND in High-Grade Endometrial Cancer
SLNB is a viable option for the surgical staging of endometrial cancer, demonstrating high diagnostic accuracy and sensitivity with minimal false negatives.
LACE trial: Laparoscopy vs. Open for Endometrial Cancer
Among women with stage I endometrial cancer, TLH is equivalent to TAH in terms of disease-free survival, supporting the use of laparoscopic surgery.